These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25371066)

  • 1. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
    Valent P; Sadovnik I; Ráčil Z; Herrmann H; Blatt K; Cerny-Reiterer S; Eisenwort G; Lion T; Holyoake T; Mayer J
    Eur J Clin Invest; 2014 Dec; 44(12):1239-45. PubMed ID: 25371066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
    Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
    Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow Cytometry Assessment of CD26
    Raspadori D; Pacelli P; Sicuranza A; Abruzzese E; Iurlo A; Cattaneo D; Gozzini A; Galimberti S; Baratè C; Pregno P; Nicolosi M; Sorà F; Annunziata M; Luciano L; Caocci G; Moretti S; Sgherza N; Fozza C; Russo S; Usala E; Liberati MA; Ciofini S; Trawinska MM; Gozzetti A; Bocchia M
    Cytometry B Clin Cytom; 2019 Jul; 96(4):294-299. PubMed ID: 30714299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotyping and Target Expression Profiling of CD34
    Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
    Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
    Sharma P; Sachdeva MUS; Naseem S; Sreedharanunni S; Das R; Malhotra P; Varma N
    Int J Lab Hematol; 2022 Jun; 44(3):518-523. PubMed ID: 35142061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
    Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
    Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
    Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevärn B; Olofsson T; Olsson-Strömberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H;
    Leukemia; 2013 Jul; 27(7):1520-6. PubMed ID: 23328954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.
    Culen M; Borsky M; Nemethova V; Razga F; Smejkal J; Jurcek T; Dvorakova D; Zackova D; Weinbergerova B; Semerad L; Sadovnik I; Eisenwort G; Herrmann H; Valent P; Mayer J; Racil Z
    Oncotarget; 2016 May; 7(22):33016-24. PubMed ID: 27145281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD26 expression on circulating CD34+/CD38- progenitor population is a specific and reliable tool for the rapid flow cytometric diagnosis of chronic myeloid leukemia-A single-center validation study.
    Rahman K; Singh MK; Chandra D; Gupta R; Sarkar MK; Gupta P; Gupta A; Yadav S; Kashyap R; Nityanand S
    Int J Lab Hematol; 2022 Jun; 44(3):524-530. PubMed ID: 35315228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
    Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen BT; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
    Clin Cancer Res; 2016 Aug; 22(16):4030-8. PubMed ID: 27006491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
    Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
    Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
    Blood; 2017 Apr; 129(17):2384-2394. PubMed ID: 28122740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
    Chen Y; Li D; Li S
    Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
    Janssen JJ; Deenik W; Smolders KG; van Kuijk BJ; Pouwels W; Kelder A; Cornelissen JJ; Schuurhuis GJ; Ossenkoppele GJ
    Leukemia; 2012 May; 26(5):977-84. PubMed ID: 22157734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing CML LSCs from HSCs using CD26.
    Jiang X
    Blood; 2014 Jun; 123(25):3851-2. PubMed ID: 24948622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
    Valent P
    Br J Haematol; 2008 Jul; 142(3):361-78. PubMed ID: 18540942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNome profiling of LSC-enriched CD34
    Ruiz MS; Sánchez MB; Bonecker S; Furtado C; Koile D; Yankilevich P; Cranco S; Custidiano MDR; Freitas J; Moiraghi B; Pérez MA; Pavlovsky C; Varela AI; Ventriglia V; Sánchez Ávalos JC; Larripa I; Zalcberg I; Mordoh J; Valent P; Bianchini M
    Front Pharmacol; 2020; 11():612573. PubMed ID: 33569005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.